Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 262-634-6 | CAS number: 61167-58-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 13 Feb - 15 May 1984
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 984
- Report date:
- 1984
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- adopted Sep 1998
- Deviations:
- not specified
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- 2-(1,1-dimethylethyl)-6-[[3-(1,1-dimethylethyl)-2-hydroxy-5-methylphenyl]methyl]-4-methylphenyl acrylate
- EC Number:
- 262-634-6
- EC Name:
- 2-(1,1-dimethylethyl)-6-[[3-(1,1-dimethylethyl)-2-hydroxy-5-methylphenyl]methyl]-4-methylphenyl acrylate
- Cas Number:
- 61167-58-6
- Molecular formula:
- C26H34O3
- IUPAC Name:
- 2-tert-butyl-6-[(3-tert-butyl-2-hydroxy-5-methylphenyl)methyl]-4-methylphenyl prop-2-enoate
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- The strain of rat was selected as a series of studies with the test substance was already performed in rats of this strain and compiled data were available at the testing facility.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Japan, Inc.
- Age at study initiation: 5 weeks
- Weight at study initiation: 132 - 173 g (females) and 173 - 216 g (males)
- Housing: 3 rats per cage were housed in plastic cages (41 x 26 x 20 cm) with hardwood chip bedding.
- Diet: Powdered diet CE-2 (CLEA Jpan, Inc., Tokyo, Japan), ad libitum
- Water: Drinking water (Ichinomiya City tap water), ad libitum
- Acclimation period: 1 week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 60 ± 10
- Air changes (per hr): more than 15 times
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 23 Nov 1983 To: 22 Dec 1983
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- corn oil
- Details on oral exposure:
- DIET PREPARATION
The test material was incorporated at the required levels (without correction for the purity) into basal diet and mixed with a blender.
- Rate of preparation of diet (frequency): Weekly
VEHICLE
- Justification for use and choice of vehicle: Corn oil was added to all diets before mixing in order to prevent contamination with test material as dust.
- Concentration in vehicle: 2% - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- In order to analyze the content of the test material in the prepared diet, samples of the prepared diets were shipped to the sponsor. Analyses of stability and homogeneity of test material in the prepared diet had been performed prior to the commencement of the study. The homogeneity was satisfactory, and it was confirmed that test material in the diet was stable for 3 weeks in a freezer. The content of test material in the prepared diets was analyzed at every preparation. The prepared diet was started to use when the content values were confirmed to be within the acceptable range. Average contents of the test material were 2431, 4809, 9854 and 29431 ppm for the nominal concentrations of 2500, 5000, 10000 and 30000 ppm in the prepared diet, respectively.
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 7 days/week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 2 500 ppm
- Remarks:
- equivalent to 252.4 mg/kg bw/day for females and 175.1 mg/kg bw/day for males
- Dose / conc.:
- 5 000 ppm
- Remarks:
- equivalent to 506.9 mg/kg bw/day for females and 344.1 mg/kg bw/day for males
- Dose / conc.:
- 10 000 ppm
- Remarks:
- equivalent to 1019.3 mg/kg bw/day for females and 699.7 mg/kg bw/day for males
- Dose / conc.:
- 30 000 ppm
- Remarks:
- equivalent to 3281.3 mg/kg bw/day for females and 2193.3 mg/kg bw/day for males
- No. of animals per sex per dose:
- 24 (12 animals per group were euthanized and necropsied after 6 weeks treatment with the test substance)
- Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: The dietary levels in this study were set by considering the results of a previous 28 days repeated dose toxicity study entitled at the same testing facility. No treatment related changes were observed in the highest dietary level of 30000 ppm group, the dietary level of 30000 ppm was selected as the highest dose level for this study, then 10000, 5000, 2500 ppm were selected as higher middle, lower middle and low dietary levels, respectively.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes, all animals were checked for general conditions and mortality
- Time schedule: Once daily
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly
FOOD CONSUMPTION AND COMPOUND INTAKE: Yes
Two-day food consumption per cage was measured weekly, and mean daily food consumption values per rat were calculated from the number of animals housed in one cage and the number of days. Test material intake was calculated from the nominal dietary levels, group means of food consumption and body weight data.
FOOD EFFICIENCY: Yes
Food efficiency was calculated according to a standard method.
WATER CONSUMPTION: Yes
Two-day water consumption per cage was measured weekly, and mean daily water consumption values per rat were calculated from the number of animals housed in one cage and the number of days.
HAEMATOLOGY: Yes, blood samples were collected via the abdominal aorta under ether anesthesia at pretreatment and after experimental week 6 or 13. EDTA-2K was used as anticoagulant. Wright-Diemsa solution was used for the determination of differential white blood cell percentages
- Anaesthetic used for blood collection: Yes (ether)
- Animals fasted: Yes, overnight
- How many animals: All
- Parameters checked: red blood cell count (RBC), white blood cell count (WBC), haemoglobin (HB), haematocrit (HT), platelet count (PLT), differential white blood cell percentages and differential count of WBC (myelocytes, neutrophils (stab), neutrophils (segment), lymphocytes, monocytes, eosinophils, basophils)
CLINICAL CHEMISTRY: Yes
- Animals fasted: Yes, overnight
- How many animals: All
- Parameters checked: Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total cholesterol, total proteins, albumin/globulin ratio (A/G), blood urea nitrogen, sodium (Na), potassium (K), Na/K ratio (Na/K), glucose and albumin
URINALYSIS: Yes
- Time schedule for collection of urine: Fresh urine samples were collected from the animals for scheduled necropsy at pretreatment and week 6 or 13, and were subjected to the urinalysis.
- Parameters checked: pH, proteins, glucose, ketones, bilirubin, occult blood and urobilinogen - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, all animals for scheduled necropsy were euthanized by exsanguination under ether anesthesia at pretreatment and after experimental week 6 or 13, and subjected to gross pathological examination for body surface and internal organs.
- Organs weights were recorded using an electric balance (1205MP, Sartorius K.K., Tokyo, Japan) after gross pathological examination: Brain, thymus, heart, lungs, liver, spleen, kidneys, adrenals, ovaries, testes and pituitary
HISTOPATHOLOGY: Yes, after fixation in 10% buffered formalin solution, the organs and tissues were routinely trimmed, embedded in paraffin wax, sectioned, and stained with hematoxylin and eosin (H&E), and then examined under light microscopically. In addition, bone tissues were decalcified by the rapid decalcification method, and processed for histopathological slides.
- Organs checked: Heart, lymph nodes (mandibular, mesenteric), spleen, bone and bone marrow (femur), thymus, adrenals, pituitary, lungs, stomach, small intestine (duodenum, jejunum, ileum), large intestine (cecum, colon, rectum), pancreas, liver, kidneys, ovaries, testes, spinal cord, brain (cerebrum, cerebellum), and any gross lesions - Statistics:
- Statistical comparisons between control and test material treated groups of numerical data for body weights, hematology data, clinical chemistry data and organ weights (absolute and relative) were assessed using the Student’s t-test. The significances of intergroup differences in incidences of findings of gross- and histopathology were analyzed by the Fisher’s exact probability test. The significance of differences for each parameters were analyzed and evaluated at 5 % (p <0.05) or 1 % (p <0.01).
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males: Body weights in the 5000 ppm group were significantly lower than control values at weeks 7, 9 and 10.
Females: Body weights in the 10000 ppm group were significantly lower than control values at weeks 8 and 11, but within the control range at the end of treatment in week 13.
These effects were not considered to be related to the test material treatment, since these were transitory and not dose-dependent. - Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males: Decreased water consumptions were noted in the 30000 ppm group when compared to the control values from week 7 to week 13.
Females: Decreasing trend in water consumptions were observed in the 30000 ppm group when compared to the control values during the course of the study.
In addition, overall average water consumptions in both sexes of the 30000 ppm dose group were also reduced compared with the control group.
Since no adverse effects on general conditions, body weight, urinalysis or clinical chemistry were noted, the reduction of water consumption was not considered to be related to the test substance. - Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males:
A significantly decrease of haemoglobin values were observed in males of the 10000 ppm dose group after 6 weeks treatment with the test substance compared with the control group. After 13 weeks treatment with the test substance the hemoglobin values were within the range of the control animals.
Females:
In females of 5000, 10000 and 30000 ppm dose group a dose-dependent significantly reduced hemoglobin level after 6 weeks treatment with the test substance compared with the control group was determined.
However, the values were within the range of historical control data for rats of this strain according to data published by Charles River (reference: Charles River, Clinical Laboratory Parameters for Crl:CS (SD), March 2006). In addition, these changes were not considered to be treatment-related, since related parameters (RBC, WBC, HT and others) were not affected, and these alterations were reversible as the effects were not observed after 13-week treatment.
Please refer to Table 1 under "any other information on results incl. tables".
Reference: Charles River, Clinical Laboratory Parameters for Crl:CS (SD), March 2006; available online - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Compared to control animals significant higher values of potassium (lower value of NA/K ratio) were noted in females of 10000 and 30000 ppm dose groups after 6-week treatment. Significant increased potassium levels and significant decreased Na/K ratio were observed in females of the 5000, 10000 and 30000 ppm dose group after 13 weeks treatment with the test substance compared with control group. This effect was not considered to be related to the treatment, since the values were within acceptable range based on historical control data determined at the testing facility.
A dose-dependent significant reduction of total-cholesterol values was determined in animals exposed to 5000, 10000 and 30000 ppm compared to control animals. This effect was not considered to be related to the treatment, since the values were within acceptable range based on historical control data determined at the testing facility.
Significant higher values of alkaline phosphatase in both sexes of the 30000 ppm dose group, significant higher values of blood urea nitrogen in females of all treatment groups and males of the 30000 ppm dose group, significant higher values of albumin in females of the 30000 ppm dose group were observed after 6-weeks treatment. However, these changes were not considered to be related to the treatment, since they were not observed after 13-weeks treatment, and no related changes were found after histopathological examination.
Please refer to Table 2 and 3 under "any other information on results incl. tables". - Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- After 13 weeks treatment with the test substance only traces of occult blood were observed in 1/12 females of the control group and the 5000 ppm dose group, respectively, and in 1/12 males of the control group, 2500 and 10000 ppm dose group, respectively.
However, it was considered that these changes were not related to the treatment, and they were incidental, since dose-dependence was lacking, and any related renal change was not determined after histopathological examination. - Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males:
Significant lower absolute spleen weights (11%) were noted in males of the 5000 ppm dose group compared to controls. Significant higher relative kidney weights (8% and 9%, respectively) were observed in males of the 5000 and 30000 ppm dose group, respectively. In males of the 10000 ppm dose group a significant increase of the relative testis weight (11%) was determined.
Females:
Significant lower absolute thymus weights (17%), and significant higher relative brain weights (7%) and relative heart weights (9%) were noted in females of the 10000 ppm dose group compared to controls.
The increase of the relative kidney weight was considered not to be related to the test material treatment, since absolute kidney weight was comparable to control value, and any related renal change was not observed after histopathological examination. The effects on absolute organ weights observed in the study were not considered to be related to the test material treatment, since there were no changes in the relative organ weights and the effects occurred at individual doses without dose-dependence. - Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males:
Control: Single discolored spot (lung) in 7/12 males and small discolored testis in 1/12 males
2500 ppm: Single discolored spot (lung) in 3/12 males
5000 ppm: Crust cranium (skin/subcutis) in 1/12 males after 6-week treatment; single discolored spot (lung) in 1/12 males
10000 ppm: Single discolored spot (lung) in 2/12 males, small discolored testis, multiple discolored spots (lung) and discolored area (lung) each in 1/12 males
30000 ppm: Single discolored spot (lung) in 6/12 males, crust cranium (skin/subcutis) and reddened material perigenital (skin/subcutis) each in 1/12 males
Females:
Control: Single discolored spot (lung) in 4/12 females
2500 ppm: Single discolored spot (lung) in 4/12 females
5000 ppm: Single discolored spot (lung) in 2/12 females
10000 ppm: Single discolored spot (lung) in 3/12 females - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Heart, lymphocytic accumulation:
Control: 1/12 males (grade 1)
30000 ppm: 1/12 males (grade 1)
Pituitary, Cyst:
Control: 1/12 females (grade 1)
5000 ppm: 1/12 males (grade 1)
10000 ppm: 1/12 females (grade 1)
Lung, lymphocytic accumulation:
Control: 5/12 females (grade 1), 8/12 males (grade 1), 1/12 males (grade 2)
2500 ppm: 4/12 females (grade 1), 3/12 males (grade 1), 1/12 males (grade 2)
5000 ppm: 2/12 females (grade 2), 5/12 males (grade 1)
10000 ppm: 3/12 females (grade 1), 2/12 females (grade 2), 7/12 males (grade 1), 3/12 males (grade 2)
30000 ppm: 4/12 females (grade 1), 7/12 males (grade 1)
Lung, accumulation of foamy cells:
Control: 1/12 females (grade 1), 1/12 males (grade 1)
5000 ppm: 1/12 males (grade 1)
10000 ppm: 1/12 females (grade 1), 3/12 males (grade 1)
Lung, bronchopneumonia:
5000 ppm: 2/12 females (grade 1)
Lung, calcification arteria wall:
Control: 1/12 males (grade 1)
2500 ppm: 1/12 females (grade 1), 1/12 males (grade 1)
5000 ppm: 3/12 females (grade 1), 6/12 males (grade 1)
10000 ppm: 1/12 females (grade 1), 1/12 females (grade 2), 3/12 males (grade 1)
30000 ppm: 2/12 females (grade 1)
Large intestine, parasites in lumen:
Control: 1/12 females (grade 1), 3/12 males (grade 1)
2500 ppm: 3/12 females (grade 1), 3/12 males (grade 1)
5000 ppm: 1/12 females (grade 1), 3/12 males (grade 1)
10000 ppm: 2/12 females (grade 1)
30000 ppm: 1/12 females (grade 1), 3/12 males (grade 1)
Pancreas, atrophy of acinar cells:
5000 ppm: 1/12 females (grade 1)
Liver, fatty metamorphosis:
Control: 1/12 females (grade 1), 1/12 males (grade 1)
5000 ppm: 1/12 females (grade 1), 2/12 males (grade 1)
Adrenal, fatty metamorphosis:
Control: 1/12 males (grade 1)
Testis, atrophy:
Control: 1/12 males (grade 2)
1000 ppm: 1/12 males (grade 1)
Skin/subcutis, inflammation:
30000 ppm: 1/12 males (grade 1)
Preputial-clitoral gland, cyst:
30000 ppm: 1/12 males (grade 1) - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 30 000 ppm
- Based on:
- test mat.
- Remarks:
- equivalent to 3281.3 mg/kg bw/day for females and 2193.3 mg/kg bw/day for males
- Sex:
- male/female
- Basis for effect level:
- other: No adverse and treatment-related effects observed up to and including the highest tested dose level.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 3 281.3 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: No adverse and treatment-related effects observed up to and including the highest tested dose level.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 2 193.3 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: No adverse and treatment-related effects observed up to and including the highest tested dose level.
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
Table 1: Summay of hematological data
Parameter | Control males |
1000 ppm males |
3000 ppm males |
10000 ppm males |
30000 ppm males |
Control females |
1000 ppm females |
3000 ppm females |
10000 ppm females |
30000 ppm females |
|
N | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | |
Hemoglobin (g/dL) at week 7 | Mean ± SD | 14.5± 0.4 | 14.2± 0.6 | 14.1± 0.7 | 14.0± 0.4 * | 14.2± 0.6 | 14.8± 0.7 | 14.7± 0.8 | 14.1± 0.5 ** | 14.1± 0.4 ** | 13.9± 1.3 * |
Hemoglobin (g/dL) at week 13 | Mean ± SD | 16.2± 0.9 | 15.7± 0.7 | 15.7± 0.5 | 15.7± 0.7 | 15.4± 1.0 | 15.8± 0.9 | 15.4± 0.5 | 15.5± 0.8 | 15.1± 0.5 * | 15.1± 0.9 |
* Significantly different from control group at p < 0.05
** Significantly different from control group at p < 0.01
Table 2: Summary of clinical chemistry data
Parameter | Control males |
1000 ppm males |
3000 ppm males |
10000 ppm males |
30000 ppm males |
Control females |
1000 ppm females |
3000 ppm females |
10000 ppm females |
30000 ppm females |
|
N | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | |
Aspartate aminotransferase (KU) at week 7 |
Mean ± SD | 127 ± 32 | 140 ± 36 | 124 ± 28 | 130 ± 34 | 141 ± 28 | 118± 23 | 125 ± 25 | 124 ± 22 | 132 ± 29 | 139 ± 30 |
Aspartate aminotransferase (KU) at week 13 |
Mean ± SD | 131 ± 39 | 121 ± 24 | 133 ± 35 | 140 ± 35 | 134 ± 49 | 119 ± 35 | 110 ± 24 | 118 ± 21 | 114 ± 19 | 115 ± 21 |
Alanine aminotransferase (KU) at week 7 |
Mean ± SD | 26 ± 6 | 29 ± 7 | 32 ± 6 * | 29 ± 6 | 30 ± 7 | 23 ± 6 | 27 ± 4 | 28 ± 4 * | 29 ± 8 * | 28 ± 10 |
Alanine aminotransferase (KU) at week 13 |
Mean ± SD | 25 ± 8 | 25 ± 4 | 28 ± 9 | 29 ± 9 | 26 ± 7 | 31 ± 14 | 29 ± 4 | 25 ± 6 | 26 ± 5 | 27 ± 6 |
Total cholesterol (mg/dL) at week 7 |
Mean ± SD | 54 ± 8 | 55 ± 8 | 52 ± 11 | 55 ± 9 | 52 ± 6 | 62 ± 13 | 62 ± 13 | 63 ± 9 | 61 ± 12 | 58 ± 12 |
Total cholesterol (mg/dL) at week 13 |
Mean ± SD | 73 ± 16 | 67 ± 20 | 57 ± 9 ** | 53 ± 16 ** | 57 ± 13 * | 71 ± 8 | 80 ± 13 | 71 ± 8 | 75 ± 10 | 73 ± 17 |
Potassium (meq/L) at week 7 | Mean ± SD | 4.9 ± 0.3 | 5.1 ± 0.4 | 4.9 ± 0.3 | 5.2 ± 0.4 | 5.4 ± 0.4 ** | 4.6 ± 0.2 | 4.7 ± 0.3 | 4.7 ± 0.4 | 4.9 ± 0.4 * | 4.9 ± 0.3 * |
Potassium (meq/L) at week 13 | Mean ± SD | 4.8 ± 0.3 | 4.7 ± 0.5 | 4.8 ± 0.4 | 4.9 ± 0.3 | 5.0 ± 0.4 | 4.0 ± 0.2 | 4.2 ± 0.3 | 4.3 ± 0.4 * | 4.4 ± 0.5 * | 4.5 ± 0.3 ** |
* Significantly different from control group at p < 0.05
** Significantly different from control group at p < 0.01
Table 3: Historical control data of CD(SD) rats at week 13 from 2 different examinations
K (meq/dL) | Na (meq/dL) | Total cholesterol (mg/dL) | |
Female | |||
N | 19 | 19 | 19 |
Mean | 4.4 | 142 | 72 |
S.D. | 0.3 | 3 | 14 |
N | 12 | 12 | 12 |
Mean | 4.4 | 143 | 78 |
S.D. | 0.4 | 1 | 13 |
Male | |||
N | 20 | 20 | 20 |
Mean | 4.7 | 143 | 49 |
S.D. | 0.6 | 1 | 7 |
N | 12 | 12 | 12 |
Mean | 4.7 | 144 | 68 |
S.D. | 0.5 | 1 | 7 |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.